Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT
A premium complete, integrated service offer for radiopharmaceuticals drug discovery and generation
Letter to the Shareholders – September 2021
Here is our September issue which echoes our #InvestorDay 2021. As usual, Philippe Genne has concocted an editorial entitled “Little GrassHopper”: a philosophical angle on the meaning of life and the importance of the individual in society.
Letter to our shareholders – November 2020
“Hunting in packs, a collaborative commercial approach hard-wired into Oncodesign’s genes” – Philippe Genne, President and CEO of Oncodesign.
Letter to our shareholders – April 2020
Here is our April 2020 issue which details the new organization of the Group into 3 Business Units. Interviews and articles on the menu. Anatomy of the new face of Oncodesign: BU Service, BU Biotech & BU Artificial Intelligence. Without forgetting the editorial by Ph. Genne entitled “how much is…
Letter to our shareholders – November 2019
“The alignment of planets is more topical than ever at the end of the year, with all due respect to the spell casters.” says Philippe Genne, CEO & founder, Oncodesign.
Letter to our shareholders – June 2019
“The health sector is in great need of innovations, & will continue to be for a long time yet” says Philippe Genne, CEO & founder, Oncodesign.
Letter to our shareholders – November 2018
“I urge you all to stay aboard and keep your eyes firmly fixed on the future: we believe in it” says Philippe Genne, CEO & founder, Oncodesign.
Letter to our shareholders – June 2018
“Step by step, we are building our future with innovation” says Philippe Genne, CEO & founder, Oncodesign.